Frankfurt - Delayed Quote EUR

Xeris Biopharma Holdings, Inc. (2B30.F)

3.6220

+0.1460

+(4.20%)

At close: April 14 at 8:20:49 AM GMT+2

Xeris Announces Changes to Its Board of Directors

CHICAGO, March 28, 2025--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced changes to its board of directors. Ricki Fairley has resigned from the board in light of other commitments, effective immediately. The Board of Directors has appointed James Brady as a new director of Xeris’ board to fill the vacancy. In addition,

Business Wire 17 days ago

XERS
Is Xeris Biopharma Holdings (XERS) The Hot Biotech Stock Under $5?

We recently published a list of 10 Hot Biotech Stocks Under $5. In this article, we are going to take a look at where Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) stands against other hot biotech stocks under $5. The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing investor attention. After […]

Insider Monkey 18 days ago

XERS
Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength?

Xeris Biopharma (XERS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks 25 days ago

XERS

AUPH
Xeris Biopharma Holdings (XERS): Among the Best Stocks to Invest in for a Stock Market Game

We recently published a list of 12 Best Stocks to Invest in for a Stock Market Game. In this article, we are going to take a look at where Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) stands against other stocks to invest in for a stock market game. We all have heard the phrase ‘value isn’t always visible […]

Insider Monkey 26 days ago

XERS
Calculating The Fair Value Of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Key Insights The projected fair value for Xeris Biopharma Holdings is US$6.17 based on 2 Stage Free Cash Flow to Equity...

Simply Wall St. 27 days ago

XERS
Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid

CHICAGO, March 17, 2025--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that its supplemental new drug application (sNDA) of Gvoke VialDx™ has received U.S Food and Drug Administration (FDA) approval for use as a diagnostic aid during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract

Business Wire 28 days ago

XERS
Xeris Biopharma Holdings Inc (XERS) Q4 2024 Earnings Call Highlights: Surpassing Revenue ...

Xeris Biopharma Holdings Inc (XERS) reports robust revenue growth and strategic advancements despite market challenges.

GuruFocus.com last month

XERS
Here's What Key Metrics Tell Us About Xeris Biopharma (XERS) Q4 Earnings

Although the revenue and EPS for Xeris Biopharma (XERS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks last month

XERS
Xeris Biopharma (XERS) Reports Q4 Loss, Misses Revenue Estimates

Xeris Biopharma (XERS) delivered earnings and revenue surprises of 57.14% and 0.81%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

XERS
Xeris Biopharma: Q4 Earnings Snapshot

The Chicago-based company said it had a loss of 3 cents per share. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 7 cents per share.

Associated Press Finance last month

XERS
Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance

CHICAGO, March 06, 2025--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the fourth quarter and full-year ended December 31, 2024 and provides full-year 2025 financial guidance.

Business Wire last month

XERS
Verrica Pharmaceuticals Inc. (VRCA) Expected to Beat Earnings Estimates: Should You Buy?

Verrica Pharmaceuticals (VRCA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks last month

VRCA

XERS
Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025

CHICAGO, February 27, 2025--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its fourth quarter and full-year 2024 financial results and provide 2025 financial guidance before the open of the U.S. financial markets on Thursday, March 6, 2025. Management will host a conference call and webc

Business Wire last month

XERS
Xeris Biopharma (XERS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Xeris Biopharma (XERS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks last month

XERS

ESPR
Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer

CHICAGO, February 24, 2025--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that Dr. Anh Nguyen has joined Xeris as Chief Medical Officer (CMO) succeeding Ken Johnson PharmD, SVP, Global Development and Medical Affairs who will retire April 1, 2025. Dr. Nguyen will develop and lead the entire product portfolio vision an

Business Wire last month

XERS
Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) top owners are retail investors with 50% stake, while 45% is held by institutions

Key Insights Significant control over Xeris Biopharma Holdings by retail investors implies that the general public has...

Simply Wall St. last month

XERS
Xeris to Participate in Upcoming Investor Conferences

CHICAGO, February 05, 2025--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will take part in the following events:

Business Wire 2 months ago

XERS
The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness

The American Diabetes Association® (ADA) and Xeris Pharmaceuticals® (Xeris BioPharma Holdings, Inc.), a national supporter of the ADA, are pleased to announce a multi-year strategic partnership to reinforce the importance of prescribing glucagon, preferably ready-to-use, for all individuals with diabetes who are treated with insulin and/or insulin secretagogues or those at high risk of hypoglycemia (low blood glucose, also called low blood sugar), in line with the ADA's recently updated Standard

PR Newswire 2 months ago

XERS
Xeris Biopharma raises FY24 revenue view to $203M from $198M-$202M

Consensus $199.7M. Xeris Biopharma (XERS) announced it expects to generate FY24 revenue of $203M, which will exceed previously announced 2024 total revenue guidance of $198M to $202M. The company also anticipates ending 2024 with over $71M in cash, cash equivalents, and short-term investments, generating positive cash flow in the fourth quarter. “We achieved another record quarter of exceptional total revenue growth with revenues expected to be $60 million for the fourth quarter and $203 million

TipRanks 3 months ago

XERS
Xeris Expects to Exceed Full-Year 2024 Financial Guidance

CHICAGO, January 10, 2025--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) today announced it expects to generate total 2024 revenue of $203 million, which will exceed previously announced 2024 total revenue guidance of $198 million to $202 million. The Company also anticipates ending 2024 with over $71 million in cash, cash equivalents, and short-term investments, generating positive cash flow in the fourth quarter.

Business Wire 3 months ago

XERS

Performance Overview

Return	2B30.F	S&P 500 (^GSPC)
YTD	+12.14%	-8.09%
1-Year	+94.31%	+5.52%
3-Year	+58.79%	+23.07%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Xeris Biopharma Holdings, Inc. (2B30.F)

Xeris Announces Changes to Its Board of Directors

Is Xeris Biopharma Holdings (XERS) The Hot Biotech Stock Under $5?

Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength?

Xeris Biopharma Holdings (XERS): Among the Best Stocks to Invest in for a Stock Market Game

Calculating The Fair Value Of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid

Xeris Biopharma Holdings Inc (XERS) Q4 2024 Earnings Call Highlights: Surpassing Revenue ...

Here's What Key Metrics Tell Us About Xeris Biopharma (XERS) Q4 Earnings

Xeris Biopharma (XERS) Reports Q4 Loss, Misses Revenue Estimates

Xeris Biopharma: Q4 Earnings Snapshot

Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance

Verrica Pharmaceuticals Inc. (VRCA) Expected to Beat Earnings Estimates: Should You Buy?

Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025

Xeris Biopharma (XERS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer

Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) top owners are retail investors with 50% stake, while 45% is held by institutions

Xeris to Participate in Upcoming Investor Conferences

The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness

Xeris Biopharma raises FY24 revenue view to $203M from $198M-$202M

Xeris Expects to Exceed Full-Year 2024 Financial Guidance

Performance Overview